Skip to main content

Table 1 Prognostic role of EZH2 in diverse cancers through OncoLnc

From: The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma

Cancer Cox P-value FDR Rank Median Mean
BLCA 0.032 7.00e-01 8.58e-01 13,285 475.71 599.61
BRCA 0.082 3.50e-01 7.03e-01 8182 395.74 504.19
CESC − 0.327 1.60e-02 2.05e-01 1239 1033.8 1118.51
COAD − 0.147 1.50e-01 5.58e-01 4290 657.07 697.51
ESCA 0.001 9.90e-01 9.95e-01 16,624 482.73 573.25
GBM − 0.037 6.90e-01 9.58e-01 12,003 598.43 689.2
HNSC − 0.158 2.40e-02 2.46e-01 1590 479.81 577.87
KIRC 0.292 2.30e-04 1.62e-03 2346 126.98 149.04
KIRP 0.527 7.90e-04 8.76e-03 1477 123.29 140.76
LAML − 0.028 8.20e-01 9.43e-01 13,200 1041.46 1043.88
LGG 0.277 6.20e-03 1.62e-02 6414 216.22 286.97
LIHC 0.478 2.80e-06 1.23e-03 36 248.55 306.71
LUAD 0.097 1.80e-01 4.10e-01 7248 320.93 397.7
LUSC − 0.088 1.90e-01 7.01e-01 4467 629.89 713.28
OV − 0.003 9.70e-01 9.93e-01 16,448 503.56 601.14
PAAD 0.228 4.10e-02 1.63e-01 4299 207.07 238.52
READ − 0.188 3.80e-01 9.57e-01 6463 643.34 675.6
SARC 0.133 2.00e-01 4.83e-01 6586 440.14 578.62
SKCM 0.052 4.40e-01 6.36e-01 11,030 447.42 528.58
STAD − 0.169 5.30e-02 3.49e-01 2548 483.32 521.53
UCEC 0.121 3.00e-01 9.88e-01 4955 460.41 528.01
  1. Significantly different results are displayed in this table (P < 0.05)